Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Development of Opsonic Mouse Monoclonal Antibodies against Multidrug-Resistant Enterococci (CROSBI ID 275201)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Kalfopoulou, Ermioni ; Laverde, Diana ; Miklic, Karmela ; Romero-Saavedra, Felipe ; Malic, Suzana ; Carboni, Filippo ; Adamo, Roberto ; Lenac Rovis, Tihana ; Jonjic, Stipan ; Huebner, Johannes Development of Opsonic Mouse Monoclonal Antibodies against Multidrug-Resistant Enterococci // Infection and immunity, 87 (2019), 9; e00276, 19. doi: 10.1128/IAI.00276-19

Podaci o odgovornosti

Kalfopoulou, Ermioni ; Laverde, Diana ; Miklic, Karmela ; Romero-Saavedra, Felipe ; Malic, Suzana ; Carboni, Filippo ; Adamo, Roberto ; Lenac Rovis, Tihana ; Jonjic, Stipan ; Huebner, Johannes

engleski

Development of Opsonic Mouse Monoclonal Antibodies against Multidrug-Resistant Enterococci

Multidrug-resistant enterococci are major causes of hospital-acquired infections. Immunotherapy with monoclonal antibodies (MAbs) targeting bacterial antigens would be a valuable treatment option in this setting. Here, we describe the development of two MAbs through hybridoma technology that target antigens from the most clinically relevant enterococcal species. Diheteroglycan (DHG), a well- characterized capsular polysaccharide of Enterococcus faecalis, and the secreted antigen A (SagA), an immunogenic protein from Enterococcus faecium, are both immunogens that have been proven to raise opsonic and cross- reactive antibodies against enterococcal strains. For this purpose, a conjugated form of the native DHG with SagA was used to raise the antibodies in mice, while enzyme-linked immunosorbent assay and opsonophagocytic assay were combined in the selection process of hybridoma cells producing immunoreactive and opsonic antibodies targeting the selected antigens. From this process, two highly specific IgG1(kappa) MAbs were obtained, one against the polysaccharide (DHG.01) and one against the protein (SagA.01). Both MAbs exhibited good opsonic killing against the target bacterial strains: DHG. 01 showed 90% killing against E. faecalis type 2, and SagA.01 showed 40% killing against E. faecium 11231/6. In addition, both MAbs showed cross-reactivity toward other E. faecalis and E. faecium strains. The sequences from the variable regions of the heavy and light chains were reconstructed in expression vectors, and the activity of the MAbs upon expression in eukaryotic cells was confirmed with the same immunological assays. In summary, we identified two opsonic MAbs against enterococci which could be used for therapeutic or prophylactic approaches against enterococcal infections.

DHG ; Enterococcus faecalis ; Enterococcus faecium ; SagA ; capsular polysaccharide ; diheteroglycan ; hybridoma technology ; monoclonal antibodies ; opsonic ; opsonophagocytic assay

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

87 (9)

2019.

e00276

19

objavljeno

0019-9567

1098-5522

10.1128/IAI.00276-19

Povezanost rada

Temeljne tehničke znanosti

Poveznice
Indeksiranost